ASH 2018: Pipeline-Aktivitäten von Amgen

3. Dezember 2018 | Kategorie: Pharmaindustrie

Amgen wird auf dem 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego (1.-4.12.2018) neue Ergebnisse zu unterschiedlichsten Entitäten mit der BiTE® Immunotherapy Platform in 45 abstracts präsentieren, darunter „First-in-Human Data“ zu AMG 420 beim Multiplen Myelom und AMG 330 bei AML.

Langzeitdaten zu Blinatumomab zeigen einen Benefit für das Erreichen eines kompletten MRD-Ansprechens bei Erwachsenen mit ALL.
Außerdem werden Ergebnisse der CoMMpass-Studie zu Carfilzomib beim neu diagnostizierten MM präsentiert.

BiTE® bei verschiedenen hämatologischen Malignomen

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Abstract #25, Oral Presentation, Saturday, Dec. 1 at 7:30 a.m. PT in Manchester Grand Hyatt San Diego, Seaport Ballroom F

Open-Label, Phase 2 Study of Blinatumomab as Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Abstract #400, Oral Presentation, Sunday, Dec. 2 at 12:45 p.m. PT in Marriott Marquis San Diego Marina, Pacific Ballroom 20

Treatment with AMG 420, an anti-B-Cell Maturation Antigen (BCMA) Bispecific T-cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
Abstract #1010, Oral Presentation, Monday, Dec. 3 at 6:30 p.m. PT in San Diego Convention Center, Ballroom 20D

Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months
Abstract #554, Oral Presentation, Monday, Dec. 3 at 7:15 a.m. PT in San Diego Convention Center, Ballroom 20A

MM

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 ASPIRE and ENDEAVOR Trials
Abstract #1964, Poster Presentation, Saturday Dec. 1 at 6:15 p.m. PT in San Diego Convention Center, Hall GH

Efficacy and Safety of Once-weekly vs Twice-weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) by Prior Lines
Abstract #3244, Poster Presentation, Sunday, Dec. 2 from 6 p.m. PT in San Diego Convention Center, Hall GH

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients With Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed by Age Group
Abstract #3277, Poster Presentation, Sunday, Dec. 2 from 6:00 p.m. PT in San Diego Convention Center, Hall GH

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Real-World Patients With Newly Diagnosed Multiple Myeloma: Results from a Prospective, Longitudinal, Observational Study (CoMMpass)
Abstract #799, Oral Presentation, Monday, Dec. 3 at 2:45 p.m. PT in San Diego Convention Center, Room 6F

Could Patients with Multiple Myeloma (MM) Derive Additional Benefit From Their Treatments? Real World Evidence for Carfilzomib Dosing Intensity on Survival and Treatment Progression
Abstract #836, Oral Presentation, Monday, Dec. 3 at 3 p.m. PT in San Diego Convention Center, Room 25B

A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Abstract #803, Oral Presentation, Monday, Dec. 3 at 3:45 p.m. PT in San Diego Convention Center, Room 6F

Quelle: Amgen


Schlagworte:

Kommentare sind geschlossen

Diese Website nutzt den Dienst 'Google Analytics', welcher von der Google lnc. (1600 Amphitheatre Parkway Mountain View, CA 94043, USA) angeboten wird, zur Analyse der Websitebenutzung durch Nutzer. Der Dienst verwendet 'Cookies' - Textdateien, welche auf Ihrem Endgerät gespeichert werden. Falls Sie kein Tracking durch Google Analytics wünschen, klicken Sie bitte hier: Google Analytics Tracking deaktivieren. Weitere Informationen

Die Cookie-Einstellungen auf dieser Website sind auf "Cookies zulassen" eingestellt, um das beste Surferlebnis zu ermöglichen. Wenn du diese Website ohne Änderung der Cookie-Einstellungen verwendest oder auf "Akzeptieren" klickst, erklärst du sich damit einverstanden.

Schließen